OVOnanong Vorasin

Onanong Vorasin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Onanong Vorasin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chawanee Thongpanchang

    National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand

    1 shared publication
  • Nitipol Srimongkolpithak

    National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand

    1 shared publication
  • Nongluck Jaito

    Hokkaido University Research Faculty of Agriculture Sapporo

    1 shared publication
  • Onsiri Srikun

    Government Pharmaceutical Organization (GPO) Bangkok Thailand

    1 shared publication
  • Pornthip Aunbamrung

    National Center for Genetic Engineering and Biotechnology (BIOTEC) National Science and Technology Development Agency (NSTDA) Pathum Thani Thailand

    1 shared publication
  • Saharat Techapanalai

    National Center for Genetic Engineering and Biotechnology (BIOTEC) National Science and Technology Development Agency (NSTDA) Pathum Thani Thailand

    1 shared publication

Latest Publications

  • From Batch to Continuous Flow Synthesis in Enzymatic Process Towards Molnupiravir

    by Siriwat Hongnak, Onanong Vorasin, Pornthip Aunbamrung, Saharat Techapanalai, Thanat Tiyasakulchai, Watcharin Sonwong, Nongluck Jaito, Chawanee Thongpanchang, Saowalak Whungsinsujarit, Onsiri Srikun, et al.

    Molnupiravir (1) is one among the limited therapeutic options for treating COVID‐19 infection and exhibits pan‐antiviral potency. Because of urgent demands during the COVID‐19 pandemic, a number of methods were developed to offer more efficient routes. In this report, we present a facile 2‐step and scalable synthesis of molnupiravir for batch processing and show the implementation of continuous flow biocatalysis to improve the efficiency in synthesis. Our key step entails immobilized lipase and isobutyric anhydride to facilitate regioselective esterification. In batch process, transamination of cytidine (2) provides N4‐hydroxycytidine (NHC, 3) with 75 % yield followed by esterification of NHC to give molnupiravir with 64 % yield, providing 48 % overall yield and 99.98 % purity (HPLC). Compared to batch approach in the esterification step, the continuous flow process provides similar product yield and purity and highlights the advantages including 2.42‐fold better productivity (mol/day), 2.47‐fold improved reaction time, and 30‐fold higher space‐time‐yield. The optimized batch and continuous flow biocatalysis enhance synthesis efficiency and reduce environmental impact, offering a sustainable approach for industrial molnupiravir production.